Table 2

Incidence of anti-panitumumab antibodies

Wild-Type KRAS

Mutant KRAS

All Patients*


Either Biacore or ELISA

Bioassay

Either Biacore or ELISA

Bioassay

Either Biacore or ELISA

Bioassay


Total Antibody Incidence, n1/n2 (%)

20050184

6/48 (12.5)

1/48 (2.1)

0/37 (0)

0/37 (0)

6/93 (6.5)

1/93 (1.1)

20060277

0/64 (0)

0/64 (0)

1/45 (2.2)

1/45 (2.2)

1/115 (0.9)

1/115 (0.9)

20050181

11/288 (3.8)

0/288 (0)

9/223 (4.0)

1/223 (0.4)

22/559 (3.9)

1/559 (0.2)

20050203 (Pmab + OX)

21/308 (6.8)

3/308 (1.0)

10/206 (4.9)

1/206 (0.5)

36/558 (6.5)

4/558 (0.7)

Pmab + IRI

17/400 (4.3)

1/400 (0.3)

10/305 (3.3)

2/305 (3.3)

29/767 (3.8)

3/767 (0.4)

Pmab + IRI or OX

38/708 (5.4)

4/708 (0.6)

20/511 (3.9)

3/511 (0.6)

65/1325 (4.9)

7/1325 (0.5)

Pre-existing Antibody Incidence, n3/n4 (%)

20050184

4/48 (8.3)

1/48 (2.1)

0/37 (0)

0/37 (0)

4/93 (4.3)

1/93 (1.1)

20060277

0/64 (0)

0/64 (0)

1/45 (2.2)

1/45 (2.2)

1/115 (0.9)

1/115 (0.9)

20050181

11/252 (4.4)

0/252 (0)

7/210 (3.3)

1/210 (0.5)

19/506 (3.8)

1/506 (0.2)

20050203 (Pmab + OX)

11/282 (3.9)

2/282 (0.7)

7/188 (3.7)

0/188 (0)

22/511 (4.3)

2/511 (0.4)

Pmab + IRI

15/364 (4.1)

1/364 (0.3)

8/292 (2.7)

2/292 (0.7)

24/714 (3.4)

3/714 (0.4)

Pmab + IRI or OX

26/646 (4.0)

3/646 (0.5)

15/480 (3.1)

2/480 (0.4)

46/1225 (3.8)

5/1225 (0.4)

Developing Antibody Incidence, n5/n6 (%)

20050184

2/37 (5.4)

0/37 (0)

0/26 (0)

0/26 (0)

2/68 (2.9)

0/68 (0)

20060277

0/42 (0)

0/42 (0)

0/30 (0)

0/30 (0)

0/75 (0)

0/75 (0)

20050181

0/255 (0)

0/255 (0)

3/205 (1.5)

0/205 (0)

4/501 (0.8)

0/501 (0)

20050203 (Pmab + OX)

10/264 (3.8)

1/264 (0.4)

3/178 (1.7)

1/178 (0.6)

14/480 (2.9)

2/480 (0.4)

Pmab + IRI

2/334 (0.6)

0/334 (0)

3/261 (1.1)

0/261 (0)

6/644 (0.9)

0/644 (0)

Pmab + IRI or OX

12/598 (2.0)

1/598 (0.2)

6/439 (1.4)

1/439 (0.2)

20/1124 (1.8)

2/1124 (0.2)


*All Patients includes patients with wild-type, mutant, and unknown KRAS status.

Pmab, panitumumab; IRI, irinotecan-based chemotherapy; OX, oxaliplatin-based chemotherapy; n1, number of patients with a positive antibody result at any time point; n2, number of patients with at least one immunoassay result; n3, number of patients with a positive antibody result at or before baseline; n4, number of patients with an immunoassay antibody result at or before baseline; n5, number of patients with negative or no antibody result at or before baseline and a positive antibody result at a postbaseline time point; n6, number of patients with at least one postbaseline immunoassay antibody result

Weeraratne et al. BMC Clinical Pharmacology 2011 11:17   doi:10.1186/1472-6904-11-17

Open Data